BoB@JPM: Ron Cooper, enGene

BoB@JPM: Ron Cooper, enGene

Author: Ben Comer January 26, 2026 Duration: 55:57

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026.  

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/



Navigating the complex journey from a promising scientific idea to a commercially viable therapy involves far more than lab work. Business Of Biotech, hosted by Ben Comer, exists in that crucial space where scientific ambition meets real-world execution. This podcast speaks directly to the founders, executives, and visionaries steering emerging biopharma companies, offering a grounded conversation about the non-scientific hurdles that define success. You'll hear detailed discussions on the organizational, financial, and operational realities of the industry-from securing funding and building a team to managing clinical trials, manufacturing, and regulatory pathways. Each episode leans on the hard-earned wisdom of accomplished guests who share commentary and practical best practices. The focus is consistently on the multifaceted challenges leaders face while trying to bring a company from its earliest stages to impact in the clinic and the market. For anyone involved in building a life sciences company, this podcast provides an essential, candid look at the entire ecosystem, making the daunting path of biotech entrepreneurship feel a bit more navigable and a lot less lonely.
Author: Language: English Episodes: 100

Business Of Biotech
Podcast Episodes
Steering Through Setbacks with AVEO Oncology's Michael Bailey [not-audio_url] [/not-audio_url]

Duration: 58:06
We love to hear from our listeners. Send us a message. For all the drug commercialization successes he's played a leading hand in during his tenures at GSK, Genentech, and ImClone—Androderm, Augmentin, necitumumab, and E…
Leading From Within with ISCT & Kiji's Miguel Forte, M.D. [not-audio_url] [/not-audio_url]

Duration: 59:37
We love to hear from our listeners. Send us a message. He's been a big pharma executive. He's a multi-time biotech founder and current biotech CEO. He was once a regulator. He's a physician. He serves on multiple boards.…
The Allogeneic Future with Poseida's Kristin Yarema, Ph.D. [not-audio_url] [/not-audio_url]

Duration: 1:04:44
We love to hear from our listeners. Send us a message. Kristin Yarema, Ph.D. thinks the progress of CAR T therapeutics is allogeneic. In fact, she says CAR T-cell therapies have to become a one-to-many proposition, if th…
Expanding The Proteome with ProFound's John Lepore, M.D. [not-audio_url] [/not-audio_url]

Duration: 56:38
We love to hear from our listeners. Send us a message. Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big. It began with a simple question: What if more RNAs were being translat…
From The Bench To The Boardroom with ImmunityBio's Enrique Diloné [not-audio_url] [/not-audio_url]

Duration: 1:06:39
We love to hear from our listeners. Send us a message. While organic chemistry lectures caused many of his peers at NYU to wring their hands, gnash their teeth, and question life choices, then-19-year-old Enrique Diloné…
First AI Antibody In Humans with Aulos' Aron Knickerbocker [not-audio_url] [/not-audio_url]

Duration: 1:08:52
We love to hear from our listeners. Send us a message. Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. On this week's episode of the Business of Biotech podcast, we get…
Drug Delivery Differentiators with Syncromune's Eamonn Hobbs [not-audio_url] [/not-audio_url]

Duration: 1:12:31
We love to hear from our listeners. Send us a message. Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's three phase 1 programs combine T-cell science with a proprietary drug deli…
Topical Ocular Biologics with Claris Bio's Clarke Atwell [not-audio_url] [/not-audio_url]

Duration: 58:06
We love to hear from our listeners. Send us a message. Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, ClarisBio is rewriting the ophthalmology rulebook. CEO Clark A…
C&G Regulatory Guidance with Lineage Therapeutics' Brian Culley [not-audio_url] [/not-audio_url]

Duration: 1:04:02
We love to hear from our listeners. Send us a message. When we last caught up with Brian Culley, CEO at Lineage Cell Therapeutics, it was January, 2021. A pandemic was raging. His company was moving mountains to keep its…